DiaMedica Therapeutics Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving DiaMedica Therapeutics Inc. now
Current reporting with the operating signal separated from the noise.
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q2 2024 Earnings Call Transcript
Investors are testing whether DiaMedica Therapeutics Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.DiaMedica Therapeutics Inc. (DMAC) Q2 2024 Earnings Call Transcript
Investors are testing whether DiaMedica Therapeutics Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Did DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Insiders Buy Up More Shares?
Investors are testing whether DiaMedica Therapeutics Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2018 Results
The story matters when it changes DiaMedica Therapeutics Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest DMAC filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
DiaMedica Therapeutics Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →